Skip to main content

Advertisement

Table 3 Association between single nucleotide polymorphism in target genes and day 3 parasite positivity after artemisinin combination therapy

From: Clinical and molecular surveillance of artemisinin resistant falciparum malaria in Myanmar (2009–2013)

Target gene SNP(s) Odd ratio 95% CI P
k13 K13a 6.4810 3.4095–12.3197 <0.0001
pfarps10 V127M 3.8841 1.9900–7.5808 <0.0001
pffd D193Y 2.8784 1.4456–5.7312 0.0018
pfmdr2 T484I 2.5181 1.3619–4.6559 0.0025
k13 + pfarps10 K13 + V127M 5.3470 2.919–9.7948 <0.0001
k13 + pffd K13 + D193Y 4.9164 2.7202–8.8855 <0.0001
k13 + pfmdr2 K13 + T484I 4.4647 2.4812–8.0341 <0.0001
pfarps10 + pffd V127M + D193Y 3.2796 1.8004–5.9742 0.0001
pfarps10 + pfmdr2 V127 +T484I 2.5541 1.4344–4.5478 0.0011
pffd + pfmdr2 D193Y + T484I 1.9758 1.1105–3.5152 0.0188
k13 + pfarps10 + pfmdr2 K13 + V127M + T484I 4.2245 2.3335–7.6479 <0.0001
k13 + pffd + pfmdr2 K13 + D193Y + T484I 3.4875 1.9084–6.3731 <0.0001
k13 + pfarps10 + pffd K13 + V127M + D193Y 4.8354 2.6840–8.7113 <0.0001
pfarps10 + pffd + pfmdr2 V127M + D193Y + T484I 2.2926 1.2798–4.1069 0.0044
k13 + pfarps10 + pffd + pfmdr2 K13 + V127 M + D193Y + T484I 3.7588 2.0371–6.9356 <0.0001
  1. SNP single nucleotide polymorphism, CI confidence interval, ACT artemisinin-based combination therapy
  2. aFor K13, any non-synonymous mutation in kelch propeller domain, after amino acid position 440 was analysed